---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008636"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:21:45.485256+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Indaptus appoints Walt Linscott as COO; sets 2023 annual meeting for May 25

## Summary
- Walt Linscott, previously Chief Business Officer, appointed COO effective March 22, 2023.
- Robert Martell, M.D., Ph.D. appointed to Board's Science and Technology Committee.
- Annual meeting set for May 25, 2023; stockholder proposals due by April 2, 2023.

## SEC filing metadata
- accession: 0001493152-23-008636
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223008636/0001493152-23-008636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223008636/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008636
- JSON: https://secwatch.observer/filing/0001493152-23-008636.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008636.txt

## Key facts
- Executive change
  Walt A. Linscott was appointed as Chief Operating Officer at Indaptus Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On March 22, 2023, the Board appointed Walt A. Linscott, the Company's Chief Business Officer, as the Company's Chief Operating Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315223008636/0001493152-23-008636-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.